
Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis
Ulcerative ColitisCytomegalovirus InfectionsColitis from reactivation of established cytomegalovirus (CMV) colonization can complicate the clinical course in patients with an acute flare of ulcerative colitis (UC). Accurate and timely detection of active CMV infection or disease with appropriate anti-viral therapy may reduce complications associated with acute UC flare. Limited information is available on the presence of colonic CMV infection in patients with quiescent ulcerative colitis. Prospective studies on factors associated with reactivation of CMV infection during active UC flare and its impact on disease progression are lacking. The hypothesis of this study are as follows: 1) CMV infection is prevalent in patients with ulcerative colitis irrespective of disease severity; 2) The degree of immunosuppression directly impacts CMV infection status in patients with ulcerative colitis

A Retrospective Analysis: the Influence of Caltrate Supplement on the Effect of Mesalazine in Ulcerative...
Ulcerative ColitisVitamin D Deficiency1 moreAims:Retrospectively observe the effects of Caltrate supplementation on the clinical effect of mesalazine in patients with ulcerative colitis. Design: From January 2015 to December 2020, through retrieving the clinical database of the Second Affiliated Hospital of Wenzhou Medical University, patients with active UC who accepted mesalazine treatment were enrolled. According to whether Caltrate was supplemented at the same time, the patients were divided into supplementary group and non-supplementary group. The modified Mayo score and several laboratory indicators were compared between the two groups.

Trial of a Decision Support Intervention for Adolescents and Young Adults With Ulcerative Colitis...
Ulcerative ColitisPediatricA web application decision support tool has been developed for adolescents and young adults (AYAs). The purpose of this pilot trial is to test the web application for adolescent and young adults (AYAs) with Ulcerative Colitis (UC). This research will assess acceptability, feasibility of the decision support intervention for AYA UC patients. Participants will be randomized to usual care or usual care plus the web application prior to an upcoming clinic visit in Gastroenterology. Participants will complete surveys one week after their clinic visit about decision making preferences and, for those in the intervention group, usability and acceptability of the web application.

Tolerability of Pentasa Sachet in Patients With Ulcerative Colitis
Ulcerative ColitisConfirmation of safety profile

Mesalazine (PENTASA®) in Ulcerative Colitis
Ulcerative ColitisThis non-interventional study examines whether the patient's level of information and the consideration of the patient's preference have a positive effect on the compliance and thus also on the therapeutic success.

Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity
Ulcerative ColitisThe study hypothesis is that withdrawal of carrageenan will lead to a longer, relapse free interval in patients with ulcerative colitis.

A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
Ulcerative ColitisThe purpose of this study is to evaluate long-term safety information of infliximab in patients who have participated in infliximab clinical studies in ulcerative colitis.

Fecal Biomarker Study for Patients With Ulcerative Colitis
Ulcerative ColitisThe present study will analyze fecal levels of FC and FL in UC patients who relapse (flare) while on a QD or a BID Asacol treatment regimen and compare those levels to levels of FC and FL in UC patients who do not relapse (flare).

Golimumab Trough Levels in Patients With Ulcerative Colitis
Ulcerative ColitisProactive therapeutic drug monitoring of Anti-TNFs with drug titration to a therapeutic window is associated with favorable long-term therapeutic outcomes in IBD and may be superior to reactive therapeutic drug monitoring. Moreover, many exposure-response relationship studies have shown that higher serum anti-TNF drug concentrations are associated with better clinical outcomes in IBD, suggesting that it is maybe time to go from a 'treat-to-target' to a 'treat-to trough' therapeutic approach. In this scenario, there are very limited data regarding therapeutic drug monitoring with golimumab in UC and even no data regarding a therapeutic window to target for important objectives outcomes like mucosal healing and histological remission.

Xeljanz Special Investigation for Long-term Use in UC Patients
Ulcerative ColitisSecondary data collection study: safety and effectiveness of Xeljanz in UC patients under Japanese medical practice